Extract to table

and Meridian Bio Therapeutics Limited (the "License Agreement") Form attached as Exhibit F to the License Agreement To be executed within sixty (60) days of the Effective Date (on or before December 19, 2023) Compound: PPC-4187 (Penteracitinib) FORM — FOR EXECUTION Right-click to update Table of Contents ARTICLE 1 — DEFINITIONS As used in this Quality Agreement (this "Agreement"), the following terms shall have the meanings set forth below

Capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed to them in the License Agreement

6 "Contract Manufacturing Organization" or "CMO" shall mean Alkerra Manufacturing Inc

8 "Effective Date" shall mean October 20, 2023, being the Effective Date of the License Agreement

10 "License Agreement" shall mean the Exclusive License Agreement dated October 2, 2023, effective October 20, 2023, between Penterra Pharmaceuticals Corp

11 "Penterra" shall mean Penterra Pharmaceuticals Corp